By improving APCs’ capacity to present tumor antigen peptides on their surfaces via MHC-I for CD8+ T-cells to recognize, heat-shock protein (HSP) fused to cancer vaccines may enhance the antitumor immune response [169,170]. The gene discussed is CD8A; the disease is neoplasm.